US Patent 8105612 Serum resistance factors of gram positive bacteria
Patent 8105612 was granted and assigned to Novartis on January, 2012 by the United States Patent and Trademark Office.
All edits
Edits on 4 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+136 characters)
Article
Patent abstract
A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.
Edits on 13 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08105612 Serum resistance factors of gram positive bacteria US Patent 8105612 Serum resistance factors of gram positive bacteria
Infobox
Patent Number
0810561200
Patent Number
810561200
Edits on 29 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
081056120
Date of Patent
January 31, 2012
0Patent Application Number
119202740
Date Filed
May 12, 2006
0Patent Primary Examiner
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
081056120
Date of Patent
January 31, 2012
0Patent Application Number
119202740
Date Filed
May 12, 2006
0Patent Primary Examiner
Edits on 14 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08105612 Serum resistance factors of gram positive bacteria
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08105612
Date of patent
January 31, 2012
Patent application number
11920274
Date Filed
May 12, 2006
Patent primary examiner
Find more entities like US Patent 8105612 Serum resistance factors of gram positive bacteria
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
